Stallergenes Greer's dust mite allergy drug clears pivotal study, edges closer to approval
In a bid to tackle one of the most common allergens that asthma patients are sensitive to, Stallergenes Greer’s house dust mite immunotherapy is one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
